Belenos’ Keymed licensing deal delivers on Phase II win in rhinosinusitis

PartnershippositivePositive

AI Analysis

Summary

Belenos and Keymed announced a licensing deal following a Phase II win for their co-developed drug in chronic rhinosinusitis with nasal polyps (CRSwNP). The companies plan to initiate Phase III studies for the candidate.

Clinical Trial Data

Phase

Phase II

Primary Endpoint

Met

Outcome Details

Phase II win in rhinosinusitis, licensing deal agreed

Importance:6/10

Sentiment:

0.70

licensing dealpartnershipPhase II datarhinosinusitisCRSwNPPhase III planning

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on August 12, 2026 2:01 PM

Read Original